Details of Disease

General Information of Disease (ID: DISVH62W)

Disease Name Pruritus
Disease Class EC90: Pruritus
Disease Hierarchy
DIS01GPL: Grass pollen hypersensitivity
DISVH62W: Pruritus
ICD Code
ICD-11
ICD-11: EC90
ICD-10
ICD-10: L29, L29.9
ICD-9
ICD-9: 698
Expand ICD-11
'EC90
Expand ICD-10
'L29; 'L29.9
Expand ICD-9
698
Disease Identifiers
MESH ID
D011537
MedGen ID
19534
HPO ID
HP:0000989
SNOMED CT ID
418290006

Drug-Interaction Atlas (DIA) of This Disease

Drug-Interaction Atlas (DIA)
This Disease is Treated as An Indication in 39 Approved Drug(s)
Drug Name Drug ID Highest Status Drug Type REF
(S)-(+)-Dimethindene maleate DMMHNU2 Approved Small molecular drug [1]
Ammonium lactate DMXMHBB Approved Small molecular drug [2]
Antazoline DMA04JS Approved Small molecular drug [3]
Azatadine DMZ80SB Approved Small molecular drug [4]
Benzocaine DMI18HW Approved Small molecular drug [5]
Benzyl alcohol DMBVYDI Approved Small molecular drug [6]
Brompheniramine DMFOVSD Approved Small molecular drug [7]
Bupivacaine DM4PRFC Approved Small molecular drug [8]
Carbinoxamine DMCT31R Approved Small molecular drug [9]
Clemastine DMBZWQL Approved Small molecular drug [10]
Crotamiton DM2TUCU Approved Small molecular drug [11]
Cyproheptadine DM92AH3 Approved Small molecular drug [12]
Dexbrompheniramine DMKVWGE Approved Small molecular drug [13]
Dexchlorpheniramine Maleate DMA8DPN Approved Small molecular drug [14]
Dibucaine DMF9G7L Approved Small molecular drug [15]
Difelikefalin DMHZBEO Approved NA [16]
Diphenylpyraline DMW4X37 Approved Small molecular drug [17]
Doxepin DMPI98T Approved Small molecular drug [18]
Doxylamine DMKOXFE Approved Small molecular drug [19]
Dyclonine DMU6OFP Approved Small molecular drug [20]
Emedastine DM36LAJ Approved Small molecular drug [21]
Hydroxyzine DMF8Y74 Approved Small molecular drug [22]
Lidocaine DML4ZOT Approved Small molecular drug [23]
Maralixibat DMJCF1O Approved Small molecular drug [24]
Menthol DMG2KW7 Approved Small molecular drug [25]
Mepyramine DMB4SFH Approved Small molecular drug [26]
Methdilazine DMAUHQX Approved Small molecular drug [27]
Naloxone DM3FXMA Approved Small molecular drug [28]
Odevixibat DMYN391 Approved Small molecular drug [29]
Phenindamine DMDTC7R Approved Small molecular drug [30]
Pheniramine DMCH7RU Approved Small molecular drug [31]
Pramoxine DMZ2LGD Approved Small molecular drug [32]
Promazine DMZAL7W Approved Small molecular drug [33]
Terbutaline DMD4381 Approved Small molecular drug [34]
Tetracaine DM9J6C2 Approved Small molecular drug [35]
Trimeprazine DMEMV9D Approved Small molecular drug [36]
Tripelennamine DMZBU15 Approved Small molecular drug [37]
Triprolidine DM7SWIA Approved Small molecular drug [38]
Chlorphenamine DM6C4YJ Phase 4 NA [39]
------------------------------------------------------------------------------------
⏷ Show the Full List of 39 Drug(s)
This Disease is Treated as An Indication in 13 Clinical Trial Drug(s)
Drug Name Drug ID Highest Status Drug Type REF
Asimadoline DMND3AB Phase 3 Small molecular drug [28]
A277 DMIYY96 Phase 2 Small molecule [40]
GSK2330672 DM4BTH8 Phase 2 NA [28]
M-516102 DMEHFRS Phase 2 NA [41]
NST-141 DMF08PA Phase 2 NA [42]
PA101 DMAMMPD Phase 2 NA [28]
SDZ-281-240 DMPZ67G Phase 2 NA [43]
SNA-120 DMPN314 Phase 2 NA [28]
SRD-174 DMUR67F Phase 2 NA [44]
ALPHA-FMH DMP9VXQ Phase 1 Small molecular drug [45]
CZEN-001 DMUF682 Phase 1 NA [46]
SNA-125 DM8L1GJ Phase 1 NA [28]
Vixarelimab DMB1NE2 Phase 1 Antibody [47]
------------------------------------------------------------------------------------
⏷ Show the Full List of 13 Drug(s)
This Disease is Treated as An Indication in 69 Patented Agent(s)
Drug Name Drug ID Highest Status Drug Type REF
3-amino-5-benzyl-substituted indazole derivative 1 DMFDURZ Patented NA [48]
Azaindazole amide derivative 1 DMJWH4B Patented NA [48]
Bicyclic heteroaryl benzamide derivative 1 DMTBWC9 Patented NA [48]
Bicyclic heteroaryl benzamide derivative 2 DM5MT4R Patented NA [48]
Bicyclic heteroaryl benzamide derivative 3 DM54EV2 Patented NA [48]
Bicyclic heteroaryl benzamide derivative 4 DMUBDYG Patented NA [48]
Bicyclic heteroaryl benzamide derivative 5 DMFOVPT Patented NA [48]
Bicyclic heteroaryl benzamide derivative 6 DMQGYWV Patented NA [48]
Bicyclic heteroaryl benzamide derivative 7 DMM1LKF Patented NA [48]
Bicyclic heteroaryl benzamide derivative 8 DMVBQJ1 Patented NA [48]
Bicyclic heteroaryl benzamide derivative 9 DMGONY4 Patented NA [48]
Five membered heterocyclic benzamide derivative 1 DMPFAST Patented NA [48]
Five membered heterocyclic benzamide derivative 2 DM4U63E Patented NA [48]
Five membered heterocyclic benzamide derivative 3 DMUS4Z0 Patented NA [48]
Imidazo pyridine derivative 1 DMCXHGW Patented NA [48]
N-(phenylpyrazolyl)benzamide derivative 1 DM0ZJX7 Patented NA [48]
N-acylpiperidine ether derivative 1 DM5GCUR Patented NA [48]
N-acylpiperidine ether derivative 2 DM02RQ4 Patented NA [48]
N-acylpiperidine ether derivative 3 DMXWE5R Patented NA [48]
N-acylpiperidine ether derivative 4 DMBUQDR Patented NA [48]
N-acylpiperidine ether derivative 5 DMQ2MKT Patented NA [48]
N-acylpiperidine ether derivative 6 DMAS01P Patented NA [48]
N-acylpiperidine ether derivative 7 DMCJR4N Patented NA [48]
N-acylpyrrolidine ether derivative 1 DMQ4ULC Patented NA [48]
N-acylpyrrolidine ether derivative 2 DMK4Y71 Patented NA [48]
PMID28270021-Compound-WO2010077680 103 DM437ZC Patented NA [48]
PMID28270021-Compound-WO2010077680 109 DMNUA21 Patented NA [48]
PMID28270021-Compound-WO2010077680 201 DMQAZMC Patented NA [48]
PMID28270021-Compound-WO2010077680 481 DM6VAS2 Patented NA [48]
PMID28270021-Compound-WO2010077680 495 DMQ9CBS Patented NA [48]
PMID28270021-Compound-WO2010077680 803 DM6TJU0 Patented NA [48]
PMID28270021-Compound-WO2010077680 811 DM47FNS Patented NA [48]
PMID28270021-Compound-WO2013009582Example16 DMVS7CJ Patented NA [48]
PMID28270021-Compound-WO2013009582Example76 DMQK4IX Patented NA [48]
PMID28270021-Compound-WO2013161919Example85-117 DM2XKTB Patented NA [48]
PMID28270021-Compound-WO2014078408Example1 DMO02EL Patented NA [48]
PMID28270021-Compound-WO2014078408Example26 DMVCBSK Patented NA [48]
PMID28270021-Compound-WO2014129431Example8-1 DMKO4ZH Patented NA [48]
PMID28270021-Compound-WO2014152663 701 DMA04P6 Patented NA [48]
PMID28270021-Compound-WO2015042088Example11 DM16URY Patented NA [48]
PMID28270021-Compound-WO2015042088Example12 DMOZHGU Patented NA [48]
PMID28270021-Compound-WO2015042088Example4 DM6KXOQ Patented NA [48]
PMID28270021-Compound-WO2016054807Example1 DMD5QEL Patented NA [48]
PMID28270021-Compound-WO2016054807Example112 DMW2ZRM Patented NA [48]
PMID28270021-Compound-WO2016054807Example71 DMREZ9I Patented NA [48]
PMID28270021-Compound-WO2016054807Example80 DMPI86D Patented NA [48]
PMID28270021-Compound-WO2016054807Example82 DM9ADSN Patented NA [48]
Pyrazolo[1,5-a]pyridine derivative 1 DMH1W89 Patented NA [48]
Pyrazolo[1,5-a]pyridine derivative 2 DMLS827 Patented NA [48]
Pyrazolo[4,3-c]pyridine derivative 1 DMHRUIZ Patented NA [48]
Pyrazolo[4,3-h]quinazoline-3-carboxamide derivative 1 DMTM82B Patented NA [48]
Pyrido[3,2-d]pyrimidine derivative 2 DMRHAU4 Patented NA [48]
Pyrido[3,2-d]pyrimidine derivative 3 DM6D1XR Patented NA [48]
Pyrrolo[2,3-b]pyridine derivative 1 DMVKCQU Patented NA [48]
Pyrrolo[2,3-b]pyridine derivative 2 DM7IPWB Patented NA [48]
Pyrrolo[2,3-b]pyridine derivative 3 DMCYOL7 Patented NA [48]
Pyrrolo[2,3-d]pyrimidine derivative 3 DMTX1G4 Patented NA [48]
Pyrrolo[2,3-d]pyrimidine derivative 4 DME0WSR Patented NA [48]
Pyrrolo[3,2-c]pyridine derivative 1 DMKF8HI Patented NA [48]
Six-membered heterocyclic benzamide derivative 1 DMYFK85 Patented NA [48]
Six-membered heterocyclic benzamide derivative 2 DMX6AKV Patented NA [48]
Six-membered heterocyclic benzamide derivative 3 DMEGVD4 Patented NA [48]
Six-membered heterocyclic benzamide derivative 4 DMB0D1H Patented NA [48]
Six-membered heterocyclic benzamide derivative 5 DM0GTUH Patented NA [48]
Six-membered heterocyclic benzamide derivative 6 DMZU96C Patented NA [48]
Six-membered heterocyclic benzamide derivative 7 DM15AFI Patented NA [48]
Tri-substituted urea derivative 1 DMHGRTX Patented NA [48]
Tri-substituted urea derivative 2 DMUVPR8 Patented NA [48]
Triazolo[4,3-b]pyridazine derivative 2 DMMJ1FN Patented NA [48]
------------------------------------------------------------------------------------
⏷ Show the Full List of 69 Drug(s)
This Disease is Treated as An Indication in 5 Discontinued Drug(s)
Drug Name Drug ID Highest Status Drug Type REF
BMY-30129 DMA4UCP Discontinued in Phase 2 NA [49]
DuP-654 DMQ9IO0 Discontinued in Phase 2 Small molecular drug [50]
BL-1889 DMJ8KSJ Terminated NA [51]
DuP-983 DM872CU Terminated NA [52]
Sch-40120 DMXBJCY Terminated Small molecular drug [53]
------------------------------------------------------------------------------------
This Disease is Treated as An Indication in 2 Investigative Drug(s)
Drug Name Drug ID Highest Status Drug Type REF
Antipruritic agents DMRXJAN Investigative NA [54]
Milchsaure DM462BT Investigative Small molecular drug [11]
------------------------------------------------------------------------------------

Molecular Interaction Atlas (MIA) of This Disease

Molecular Interaction Atlas (MIA)

References

1 Prescription and safety of dimethindene maleate micropellet capsules in Hungary. Orv Hetil. 2004 Feb 15;145(7):327-9.
2 Ammonium lactate FDA Label
3 Antazoline FDA Label
4 Azatadine FDA Label
5 A double-blind, randomized clinical study to determine the efficacy of benzocaine 10% on histamine-induced pruritus and UVB-light induced slight sunburn pain. J Dermatolog Treat. 2015;26(4):367-72.
6 Benzyl alcohol FDA Label
7 Brompheniramine FDA Label
8 Bupivacaine FDA Label
9 Carbinoxamine FDA Label
10 Clemastine FDA Label
11 Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services. 2015
12 Cyproheptadine FDA Label
13 Dexbrompheniramine FDA Label
14 Dexchlorpheniramine maleate FDA Label
15 Dibucaine FDA Label
16 FDA Approved Drug Products from FDA Official Website. 2021. Application Number: 214916.
17 Diphenylpyraline FDA Label
18 Doxepin FDA Label
19 Doxylamine FDA Label
20 Dyclonine FDA Label
21 Emedastine FDA Label
22 Hydroxyzine FDA Label
23 Lidocaine FDA Label
24 FDA Approved Drug Products from FDA Official Website. 2023. Application Number: 214662.
25 methyl salicylate FDA Label
26 Pharmacology of sinomenine, an anti-rheumatic alkaloid from Sinomenium acutum. Acta Med Okayama. 1976 Feb;30(1):1-20.
27 Methdilazine FDA Label
28 Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
29 FDA Approved Drug Products from FDA Official Website. 2023. Application Number: 215498.
30 An evaluation of thephorin as an adjunct in the treatment of pruritic dermatoses. N C Med J. 1949 Sep;10(9):476-9.
31 Pheniramine FDA Label
32 Pramoxine FDA Label
33 Promazine FDA Label
34 Terbutaline FDA Label
35 Tetracaine FDA Label
36 Trimeprazine FDA Label
37 Tripelennamine FDA Label
38 Ephedrine FDA Label
39 Psychogenic Itch Management. Curr Probl Dermatol. 2016;50:124-32.
40 Clinical pipeline report, company report or official report of Klus Pharma
41 Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800034718)
42 Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800032175)
43 Clearing of psoriasis by a novel immunosuppressive macrolide. J Invest Dermatol. 1996 Apr;106(4):701-10.
44 ClinicalTrials.gov (NCT00838708) Phase IIa Safety and Efficacy Study of SRD174 Cream in Patients With AD-associated Pruritus. U.S. National Institutes of Health.
45 URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 5189).
46 Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800022785)
47 ClinicalTrials.gov (NCT03816891) A Phase 2a/b, Randomized, Double-Blind, Placebo-Controlled Study to Investigate the Efficacy, Safety, Tolerability and Pharmacokinetics of KPL-716 in Reducing Pruritus in Subjects With Prurigo Nodularis. U.S.National Institutes of Health.
48 Tropomyosin receptor kinase inhibitors: an updated patent review for 2010-2016 - Part II.Expert Opin Ther Pat. 2017 Jul;27(7):831-849.
49 Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800005019)
50 Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800003690)
51 Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800016683)
52 Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800003352)
53 Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800003693)
54 The ChEMBL database in 2017. Nucleic Acids Res. 2017 Jan 4;45(D1):D945-D954.